Prilosec Generics Stability Review By FDA To Be Completed By Mid-November
Executive Summary
FDA expects to complete its review of data submitted by AstraZeneca regarding the long-term stability of omeprazole generics in a month.
You may also be interested in...
Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes
Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes
Dr. Reddy’s Omeprazole Case: Is Pediatric Exclusivity Extension Of Patent?
Dr. Reddy's legal rationale for why it should get 180-day exclusivity for 40 mg omeprazole could include an argument that pediatric exclusivity be treated as an extension of the drug's patent life